ADCT-402 (loncastuximab tesirine), an ADC against CD19 conjugated to a PBD-dimer toxin, has recently been approved for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma, on the basis of clinical results obtained in phase I and pivotal phase II clinical trials43. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.